TY - JOUR
T1 - Abciximab prevents ischemic complications during angioplasty
AU - Roe, Matthew T.
AU - Moliterno, David J.
PY - 1998/5
Y1 - 1998/5
N2 - The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.
AB - The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.
UR - https://www.scopus.com/pages/publications/0031776440
UR - https://www.scopus.com/inward/citedby.url?scp=0031776440&partnerID=8YFLogxK
U2 - 10.3949/ccjm.65.5.267
DO - 10.3949/ccjm.65.5.267
M3 - Review article
C2 - 9599910
AN - SCOPUS:0031776440
SN - 0891-1150
VL - 65
SP - 267
EP - 272
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
IS - 5
ER -